Research Article
Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma
Table 1
Baseline characteristics of study patients.
| | | Mucosal melanoma | Uveal melanoma | | | immunotherapy | chemotherapy | | immunotherapy | chemotherapy | |
| | Number of patients | 151 | 78 | | 100 | 110 | | | Gender | | | | | | | | Female, no(%) | 106 (70.2) | 58 (74.36) | p=0.54 | 57 (57.0) | 58 (47.27) | p=0.58 | | Male, no(%) | 45 (29.8) | 20 (25.64) | | 43 (43.0) | 52 (52.73) | | | Mean age (y) at metastasis diagnosis (SD) | 66.3 (13.0) | 68.2 (12.3) | p=0.39 | 65.0 (12.5) | 62.9 (12.4) | p=0.22 | | Melanoma localization, no(%) | | | | | | | | Uveal | | | | | | | | Choroid | - | - | | 96 (96) | 107 (97.3) | p=0.71 | | Other | - | - | | 4 (4) | 3 (3) | | | Conjunctiva | 6 (4) | 3 (3.8) | p=0.99 | - | - | | | Oral cavity | 59 (39.1) | 30 (38.5) | | - | - | | | Digestive | 42 (27.8) | 22 (28.2) | | - | - | | | Urologic | 6 (4) | 2 (2.6) | | - | - | | | Gynecological | 38 (25.2) | 21 (26.9) | | - | - | | | Mutation, no/denom(%) | | | | | | | | BRAF | 6/143 (4.2) | - | | 0/66 | - | | | CKIT | 20/127 (15.7) | - | | 0/56 | - | | | NRAS | 11/99 (11.1) | - | | 0/50 | - | | | First-line immunotherapy, no(%) | | | | | | | | Anti-CTLA4 | 76 (50.3) | - | | 63 (63.0) | - | | | Anti-PD1 | 75 (49.7) | - | | 37 (37.0) | - | | | First-line chemotherapy, no(%) | | | | | | | | Fotemustine | - | 5 (6.4) | | - | 27 (24.5) | | | Dacarbazine | - | 44 (56.4) | | - | 56 (50.9) | | | other | - | 29 (37.2) | | - | 27 (24.5) | | | Treatment before immunotherapy, no (%) | 53 (35.1) | - | | 48 (48.0) | - | | | Metastasis at the first treatment, no(%) | | | | | | | | Brain | 14 (9.3) | 7 (9) | p=1.00 | 9 (9.0) | 7 (6.4) | p=0.65 | | Liver | 44 (29.1) | 36 (46.2) | p=0.016 | 79 (79.0) | 99 (90) | p=0.043 | | Cutaneous | 80 (53) | 32 (41) | p=0.11 | 15 (15.0) | 8 (7.3) | p=0.12 | | Lung | 67 (44.4) | 37 (47.4) | p=0.76 | 48 (48.0) | 28 (25.5) | p=0.001 | | Bones | 22 (14.6) | 12 (15.4) | p=1.00 | 22 (22.0) | 15 (13.6) | p=0.16 | | Lymph node | 91 (60.3) | 41 (52.6) | p=0.33 | 18 (18.0) | 11 (10) | p=0.14 | | Other | 18 (11.9) | 22 (28.2) | p=0.003 | 7 (7.0) | 26 (23.6) | p=0.003 | | Delay between initial diagnosis and first treatment, month median (Q1; Q3) | 21.4 (9.8;41.2) | 16.5 (8.9; 37.2) | p=0.30 | 59.0 (25.2;120.3) | 36.5 (21.1; 75.7) | p=0.02 |
|
|
|
